# BR101 in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT07537049** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 10 (estimated)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **BIOLOGICAL:** BR101 injection

## Key facts

- **NCT ID:** NCT07537049
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2027-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07537049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07537049, "BR101 in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07537049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*